Warren R, Armstrong A, Gooderham M, Strober B, Thaci D, Imafuku S, Sofen H, Spelman L, Korman N, Zheng M, Colston E, Throup J, Kundu S, Kisa R, Banerjee S, Blauvelt A. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin [Internet]. 2022Mar.4 [cited 2024Sep.20];6(2):s4. Available from: https://dermsquared.com/skin/article/view/1520